Navigation Links
Arobella Medical CEO is Issued U.S. Patent for Ultrasound Wound Therapy Technology
Date:10/9/2008

Patent will protect next generation of Qoustic Wound Therapy System(R)

MINNEAPOLIS, Oct. 9 /PRNewswire/ -- Arobella Medical, LLC, a leader in advanced ultrasonic wound care devices, today announced that its Co-founder, President and CEO Eliaz Babaev, Ph.D., has been issued a U.S. patent that covers technology employed in the next generation of the company's Qoustic Wound Therapy System(R).

The Qoustic Wound Therapy System, which offers a safe, cost-effective alternative to painful sharps debridement and other surgical modalities, is emerging as the gold standard for wound care. Light guidance contact produces a dual delivery of low-frequency ultrasound energy directly on the wound bed. This process gently, thoroughly and efficiently debrides the wound and provides stable cavitation to remove dead or diseased tissue, harmful bacteria and biofilm. Ultrasonic treatment also expedites healing by preserving healthy tissue and protecting granulation tissue, improving circulation through vasodilation and angiogenesis, and preparing the wound bed for more effective use of downstream therapies such as grafts and flaps.

"This patent, which is the first of many that are currently pending, will help protect the next generation of this product that is poised to become the latest breakthrough in wound care today," said Babaev.

The first generation of the Qoustic Wound Therapy System family was launched in February 2008.

About Arobella Medical, LLC

Arobella Medical, LLC is a Minneapolis-based medical device company specializing in low-frequency ultrasound for wound care and other wound management therapies. Arobella Medical is positioned to become a leader in advanced ultrasound wound care technologies and devices. Arobella Medical Co-founder and CEO Eliaz Babaev has more than 40 years of experience developing, designing and commercializing medical devices that use ultrasound, with over 40 patents worldwide. He holds a Ph.D. degree from the Moscow Bauman School, a Doctor of Science degree from the Latvia Academy of Science, and a Doctor of Science degree from the Russian State Supreme Certification Committee, all in biomedical ultrasound. For more information, go to http://www.arobella.com


'/>"/>
SOURCE Arobella Medical, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arobella Medical, LLC Launches Qoustic Wound Therapy System(TM)
2. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
3. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
4. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
5. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
6. BioMS Medical announces its intention to renew a normal course issuer bid
7. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Globus Medical Announces Record 2nd Quarter 2007 Results
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 ... $7M Series B financing, adding an additional $3M from ... by Mesa Verde Venture Partners and other strategic partners ... directed towards further accelerating commercial adoption of their flagship ... test and expanding the Paradigm cancer registry. ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, will host ... at 8:00 AM EST on Thursday, February 16, 2017 ... program, the recently announced closing of a $10.5 million ... To participate in the live call and take ...
Breaking Biology Technology:
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
Breaking Biology News(10 mins):